Examiner: ABDALHAMEED, MANAHIL MIRGHANI ALI

Tech Center 1600 • Art Units: 1622 1625 1629

This examiner grants 50% of resolved cases

Analysis

Manahil Mirghani Ali Abdalhameed serves in Tech Center 1600 and Art Unit 1622. With 150 resolved cases, the examiner has an allowance rate of 50.0 percent. This balanced rate indicates that applications have an even chance of success, requiring careful and strategic prosecution.

The interview lift is a significant 39.0 percent. This suggests that interviews are highly effective and can nearly double the chances of success for some applications. The 39.0 percent lift is one of the most important metrics for practitioners to consider when planning their approach to the 150 resolved cases handled by this examiner.

The median days to allowance is 1040. While the 50.0 percent allowance rate presents a challenge, the high interview lift offers a clear path forward. Utilizing the 39.0 percent lift may help applicants navigate the 1040-day median pendency more successfully.

Written from this page's own data; every figure is computed from USPTO records and verified before publication.

Performance Statistics

50.3%

Allow Rate

-9.7% vs TC avg

189

Total Applications

+38.2%

Interview Lift

1041

Avg Prosecution Days

Based on 151 resolved cases, 2023–2026

Rejection Statute Breakdown

2.8%

§101 Eligibility

16.7%

§102 Novelty

40.0%

§103 Obviousness

19.7%

§112 Clarity

Currently Pending Office Actions

App #	Title	Status	Assignee
18578783	OCTENIDINE COMPOSITIONS AND METHODS OF USE THEREOF	Non-Final OA	Solventum Intellectual Properties Company
18726838	PROCESS FOR ISOLATING 2,4-BIS-(2,4-DIHYDROXYPHENYL)-6-(4-METHOXYPHENYL)-1,3,5-TRIAZINE (DIOPAT)	Non-Final OA	BASF SE
18846873	THERAPEUTIC COMPOUND AND SALTS	Non-Final OA	Regents of the University of Minnesota
18390242	COMPOSITIONS AND METHOD FOR TREATING GUT PERMEABILITY CAUSED BY HYDROGEN SULFIDE PRODUCING BACTERIA	Non-Final OA	The United States Government as represented by the Department of Veterans Affairs
18259843	Methods of Treatment	Non-Final OA	Arena Pharmaceuticals, Inc.
17801486	TREATMENT FOR CHEMOBRAIN	Final Rejection	YALE UNIVERSITY
18847121	ORGANIC COMPOUNDS	Non-Final OA	INTRA-CELLULAR THERAPIES, INC.
17786949	ORAL CANNABINOID FORMULATIONS	Final Rejection	Jazz Pharmaceuticals Research UK Limited
18554980	SUBSTITUTED FUSED BICYCLIC COMPOUNDS AS PARP INHIBITORS AND THE USE THEREOF	Non-Final OA	IMPACT THERAPEUTICS (SHANGHAI), INC.

Facing This Examiner?

IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.

Build Your Strategy